IL242804B - Pridopidine to reduce functional decline in Huntington's patients - Google Patents
Pridopidine to reduce functional decline in Huntington's patientsInfo
- Publication number
- IL242804B IL242804B IL242804A IL24280415A IL242804B IL 242804 B IL242804 B IL 242804B IL 242804 A IL242804 A IL 242804A IL 24280415 A IL24280415 A IL 24280415A IL 242804 B IL242804 B IL 242804B
- Authority
- IL
- Israel
- Prior art keywords
- pridopidine
- disease patients
- functional capacity
- huntington disease
- reducing impairment
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title 1
- 230000006735 deficit Effects 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837928P | 2013-06-21 | 2013-06-21 | |
| US201361877832P | 2013-09-13 | 2013-09-13 | |
| PCT/US2014/043204 WO2014205229A1 (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL242804B true IL242804B (en) | 2022-02-01 |
Family
ID=52105289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL242804A IL242804B (en) | 2013-06-21 | 2015-11-26 | Pridopidine to reduce functional decline in Huntington's patients |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10322119B2 (enExample) |
| EP (1) | EP3010506B1 (enExample) |
| JP (1) | JP2016523862A (enExample) |
| KR (1) | KR102316933B1 (enExample) |
| CN (1) | CN105592848A (enExample) |
| AU (1) | AU2014281414A1 (enExample) |
| BR (1) | BR112015029918A2 (enExample) |
| CA (1) | CA2913781C (enExample) |
| CL (1) | CL2015003690A1 (enExample) |
| DK (1) | DK3010506T3 (enExample) |
| EA (1) | EA201690069A1 (enExample) |
| ES (1) | ES2879631T3 (enExample) |
| HK (1) | HK1221646A1 (enExample) |
| HU (1) | HUE054783T2 (enExample) |
| IL (1) | IL242804B (enExample) |
| MX (1) | MX384234B (enExample) |
| PE (2) | PE20170302A1 (enExample) |
| PH (1) | PH12015502691A1 (enExample) |
| PL (1) | PL3010506T3 (enExample) |
| SG (1) | SG11201509729YA (enExample) |
| TW (1) | TW201529069A (enExample) |
| UA (1) | UA122999C2 (enExample) |
| UY (1) | UY35624A (enExample) |
| WO (1) | WO2014205229A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2937243C (en) * | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| EP3324967A4 (en) * | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| CN110012661A (zh) * | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| AU2017326436A1 (en) * | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| US20260091028A1 (en) * | 2017-08-14 | 2026-04-02 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
| HUE061505T2 (hu) * | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) * | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3917380B1 (en) * | 2019-01-31 | 2025-03-19 | F. Hoffmann-La Roche AG | Assessing progression of huntington's disease |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| SMT202600016T1 (it) * | 2019-06-12 | 2026-03-09 | Prilenia Neurotherapeutics Ltd | Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi |
| CN114727761A (zh) * | 2019-09-17 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 患有运动障碍的患者的个性化保健的改善 |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2022094565A1 (en) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders |
| CA3214354A1 (en) * | 2021-04-14 | 2022-10-20 | Michael Hayden | Treatment of prodromal huntington disease |
| WO2025181805A1 (en) * | 2024-02-27 | 2025-09-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| EP1713486A4 (en) | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
-
2014
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active Active
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 MX MX2015017307A patent/MX384234B/es unknown
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 HK HK16109788.9A patent/HK1221646A1/zh unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en not_active Ceased
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX384234B (es) | 2025-03-14 |
| PH12015502691A1 (en) | 2016-03-14 |
| KR102316933B1 (ko) | 2021-10-26 |
| ES2879631T3 (es) | 2021-11-22 |
| CA2913781C (en) | 2022-05-10 |
| EP3010506B1 (en) | 2021-05-12 |
| HK1221646A1 (zh) | 2017-06-09 |
| UY35624A (es) | 2015-01-30 |
| JP2016523862A (ja) | 2016-08-12 |
| DK3010506T3 (da) | 2021-07-12 |
| WO2014205229A1 (en) | 2014-12-24 |
| US20140378508A1 (en) | 2014-12-25 |
| CL2015003690A1 (es) | 2016-10-28 |
| HUE054783T2 (hu) | 2021-09-28 |
| UA122999C2 (uk) | 2021-02-03 |
| WO2014205229A8 (en) | 2015-04-09 |
| CN105592848A (zh) | 2016-05-18 |
| MX2015017307A (es) | 2016-08-03 |
| PL3010506T3 (pl) | 2021-11-02 |
| CA2913781A1 (en) | 2014-12-24 |
| EP3010506A4 (en) | 2017-02-08 |
| AU2014281414A1 (en) | 2016-01-21 |
| KR20160055122A (ko) | 2016-05-17 |
| BR112015029918A2 (pt) | 2017-07-25 |
| SG11201509729YA (en) | 2015-12-30 |
| US10322119B2 (en) | 2019-06-18 |
| EA201690069A1 (ru) | 2016-06-30 |
| PE20170302A1 (es) | 2017-03-31 |
| TW201529069A (zh) | 2015-08-01 |
| EP3010506A1 (en) | 2016-04-27 |
| PE20160195A1 (es) | 2016-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2922514T (pt) | Interface de paciente birradial | |
| AU357213S (en) | Patient interface | |
| GB202005994D0 (en) | Patient interface and aspects thereof | |
| AU353287S (en) | Patient interface | |
| AU353289S (en) | Patient interface | |
| GB2584563B (en) | Patient support usable with bariatric patients | |
| GB201717384D0 (en) | Improvements in or relating to assemblies for use in replacement surgery | |
| HUE056638T2 (hu) | Telomer kiterjesztéssel kapcsolatos gyógyászati alkalmazás | |
| AU358463S (en) | Frame for patient interface | |
| IL251448B (en) | A preparation for use in reducing body fat in a patient | |
| EP2994078A4 (en) | COMPRESSIVE PATIENT-HEATING DEVICE | |
| SG11201510021TA (en) | Compositions and methods for use in medical diagnosis | |
| LT2958624T (lt) | Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas | |
| GB201309375D0 (en) | Medical methods and compounds for medical use | |
| GB201515643D0 (en) | Improvements in or relating to assemblies for use in knee replcement surgery | |
| ZA201601248B (en) | Wheelchair | |
| GB201307872D0 (en) | Medical use | |
| GB201309376D0 (en) | Medical methods and compounds for medical use | |
| ZA201503834B (en) | Identifying subjects in need of treatment | |
| GB201309379D0 (en) | Medical methods and compounds for medical use | |
| AU354914S (en) | Patient interface | |
| AU354913S (en) | Patient interface | |
| AU353572S (en) | Patient interface | |
| GB201319004D0 (en) | Medical use | |
| GB201311290D0 (en) | Medical use |